Phase II trial of extended-dosing temozolomide in patients with melanoma
Petra Rietschel(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Klaus J. Busam(Memorial Sloan Kettering Cancer Center), Katy Smith(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Katherine S. Panageas(Mayo Clinic), Scott R. Gerst(Memorial Sloan Kettering Cancer Center), Samuel Ejadi(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Achim A. Jungbluth(Gynecologic Oncology Group)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k